Updated Jul 16, 2026 · Last SEC filing 2026-07-02
Avalo Therapeutics, Inc. (AVTX) has filed 29 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-02. 8 Form 8-K material event filings were reported by AVTX in the last 90 days. 7 Form 144 notices of proposed sale were filed for AVTX stock. InsiderAlpha tracks every AVTX SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SIC classification | Pharmaceutical Preparations (SIC 2834) |
|---|---|
| SEC CIK | 0001534120 |
| Form 4 filings (90d) | 29 |
|---|---|
| Form 8-K filings (90d) | 8 |
| Form 144 notices (90d) | 7 |
| Latest Form 4 filing | 2026-07-02 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Doyle Mittie | Chief Medical Officer | M — Option exercise | 2.9K | $12.65 | $36K | SEC | |
| Doyle Mittie | Chief Medical Officer | S — Open-market sale | 4.7K | $20.00 | $93K | SEC | |
| Doyle Mittie | Chief Medical Officer | M — Option exercise | 1.8K | $8.04 | $14K | SEC | |
| Doyle Mittie | Chief Medical Officer | S — Open-market sale | 1.4K | $18.00 | $26K | SEC | |
| Doyle Mittie | Chief Medical Officer | M — Option exercise | 1.4K | $8.04 | $12K | SEC | |
| Riley Jennifer | Chief Strategy Officer | F — Tax withholding / forfeiture | 588 | $13.10 | $8K | SEC | |
| VARKI PAUL | Chief Legal Officer | F — Tax withholding / forfeiture | 1.1K | $13.10 | $14K | SEC | |
| Sullivan Christopher Ryan | Chief Financial Officer | F — Tax withholding / forfeiture | 138 | $13.10 | $2K | SEC | |
| Doyle Mittie | Chief Medical Officer | F — Tax withholding / forfeiture | 1.1K | $13.10 | $14K | SEC | |
| Doyle Mittie | Chief Medical Officer | S — Open-market sale | 679 | $16.00 | $11K | SEC | |
| Doyle Mittie | Chief Medical Officer | M — Option exercise | 679 | $8.04 | $5K | SEC | |
| NEIL GARRY ARTHUR | Chief Executive Officer | A — Grant or award | 100.2K | $0.00 | — | SEC | |
| Doyle Mittie | Chief Medical Officer | A — Grant or award | 43.5K | $0.00 | — | SEC | |
| Riley Jennifer | Chief Strategy Officer | A — Grant or award | 34.2K | $0.00 | — | SEC | |
| Sullivan Christopher Ryan | Chief Financial Officer | A — Grant or award | 39.9K | $0.00 | — | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Avalo Therapeutics, Inc. (AVTX). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Doyle Mittie | 30 | $3.77M |
| Sullivan Christopher Ryan | 14 | $2.18M |
| VARKI PAUL | 11 | $2.47M |
| Lind Kevin Robert | 2 | $17K |
| Jain Rita | 2 | $16K |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in AVTX insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live AVTX dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.